Framatome Announces New Investment Supporting Nuclear Medicine

Framatome (ENS Corporate Member) announced that it acquired a minority stake in the French startup Global Morpho Pharma.

With this investment, Framatome strengthens its activities serving nuclear medicine development and expands its support for the supply chain of Lutetium-177 and other promising isotopes for therapeutic applications.

Global Morpho Pharma is a startup founded in 2018 and based in the Nantes region of France. The company develops innovative equipment and provides value-added services to radiopharmaceutical companies for the production and distribution of medical radioisotopes.

Read the full Framatome Press Release.

 

Lutetium-177 is a beta-emitting radioisotope used for the treatment of prostate cancer and in radiopharmaceutical developments for other cancer indications. Framatome’s proprietary technology enabled the first production of Lutetium-177 in a Canadian power reactor in June 2022.

Moreover, Framatome is also supporting the development of solutions to produce Cobalt-60 in Pressurized Water Reactors (PWR) operated by Exelon Generation in the US.

This year, the European Nuclear Society dedicated several events and activities focusing on nuclear medical applications and radioisotopes production and supply.

This one has been also the key topic of the Panel Discussion, opening the last European Research Reactor Conference (RRFM) in Budapest, 6-10 June 2022.

Moreover, last February ENS organised the webinar “Radioisotopes for life. Ensuring European supply – Stakeholders and opportunities”. The final report of the event and the video are available here.